Kymera Therapeutics, Inc. has announced an update to its partnership with Sanofi regarding the advancement of a next-generation oral IRak4 degrader development candidate, KT-485. Sanofi has decided to advance KT-485 into clinical testing and will not advance KT-474. This decision comes after preclinical testing showed that KT-485 demonstrated increased selectivity and potency with a favorable safety profile compared to KT-474.
Under the collaboration, Kymera achieved a $20 million milestone related to preclinical activities associated with KT-485 and is eligible for up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of phase 1 clinical testing. Furthermore, Kymera may opt-in to a 50/50 development and profit share of KT-485 in the U.S.
KT-485, also known as SAR447971, is a first-in-class, selective, potent, oral IRak4 degrader in development for the treatment of immuno-inflammatory diseases. It targets IRak4, which is a master regulator of innate immunity and a key protein of the myddosome complex that mediates signaling through IL-1 and toll-like receptors. The molecule has the potential to achieve a broad, well-tolerated, anti-inflammatory effect, providing a novel therapeutic approach for a variety of immune-inflammatory diseases.
Kymera Therapeutics is a clinical-stage biotechnology company focused on pioneering the field of targeted protein degradation (TPD) to develop medicines for critical health problems. The company has been recognized as one of Boston’s top workplaces for the past several years.
This update reflects Sanofi and Kymera's commitment to transforming immunology treatment paradigms and bringing forward the best oral medicines to patients living with immunological diseases. The market has reacted to these announcements by moving the company's shares -0.92% to a price of $46.705. Check out the company's full 8-K submission here.
